HUTCHMED (China) Ltd
HMDCFDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
HMPL-523
Primary Immune Thrombocytopenia (ITP)
HMPL-760
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
HMPL-523(300mg PO QD)
Warm Antibody Autoimmune Hemolytic Anemia
surufatinib
Tumors
HMPL-A580
Solid Tumors, Adult
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HMPL-523 | Phase 3 | Primary Immune Thrombocytopenia (ITP) | - | - |
HMPL-760 | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | - | - |
HMPL-523(300mg PO QD) | Phase 3 | Warm Antibody Autoimmune Hemolytic Anemia | - | - |
surufatinib | Phase 2 | Tumors | - | - |
HMPL-A580 | Phase 2 | Solid Tumors, Adult | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in HUTCHMED (China) Ltd's drug pipeline?→
CatalystAlert tracks 5 drug candidates in HUTCHMED (China) Ltd's (HMDCF) pipeline across Phase 3, Phase 2. Its lead program is HMPL-523 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is HUTCHMED (China) Ltd's next FDA catalyst?→
HUTCHMED (China) Ltd's (HMDCF) next tracked catalyst is a PDUFA expected December 25, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HMDCF biotech catalysts?→
Add HMDCF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow HUTCHMED (China) Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.